Nivolumab Plus Sitravatinib Highly Active in ccRCC

Published: Sunday, Feb 16, 2020
Pavlos Msaouel, MD, of the University of Texas MD Anderson Cancer Center

Pavlos Msaouel, MD

Combining nivolumab (Opdivo) with sitravatinib induced a confirmed objective response rate (ORR) of 39% and a 92% clinical benefit rate in patients with advanced clear cell renal cell carcinoma (ccRCC).1

The efficacy data showed confirmed objective responses in 39% (n = 15) of the 38 efficacy-evaluable patients. One patient had an unconfirmed complete response. Stable disease was the best response for 20 patients. The results compared favorably with historical results for other agents, Msaouel noted: 3% to 5% for everolimus and 17% to 21% for cabozantinib (Cabometyx).


  1. Msaouel P, Thall PF, Yuan Y, et al. A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. J Clin Oncol. 2020;38(suppl 6; abstr 612).
  2. Pant S, Spira AI, Cho BC, et al. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). J Clin Oncol. 2018;36(suppl 15; abstr 4568). doi: 10.1200/JCO.2018.36.15_suppl.4568.
  3. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665.
<<< View more from the 2020 Genitourinary Cancers Symposium
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication